AnabolicSteroidHalotestinCAS76-43-7SafetyFluoxymesteroneForWomenBreastCancerTreatmentPowderAnothername:fluoxymesterone;halotestin;androfluorone;oratestin;ultandren,99%rawsteroidfluoxymesteronehalotestin,fluoxymesterone,fluoxymesteronehalotestin,fluoxymesteronerawpowder,halotest,9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-oneCAS:76-43-7EINECS:200-961-8Molecularfomular:C20H29FO3MolecularWeight:336.44Assay:99%min.Packing:Foilbagortin.Delivery:Expresscourier.Character:Whitecrystallinepowder.usedtostimulatepubertyinmaleswithdelayedpuberty.Treatingadvancedbreastcancerinwomenwhoare1to5yearspastmenopause.Keywo***:Fluoxymesterone,Halotestin,CancerTreatmentSteroidsEffectiveDose:10-40mgs/dayActivelife:6-8hoursDetectionTime:2monthsAnabolic/Androgenicratio:1,900/850skype:tracy665emailtracyatycphardotcomDescription:LikemanyC-17alphaalkylatedsteroids,fluoxymesteronehaspoorbindingtotheandrogenreceptor.Fluoxymesteroneworksbyattachingitselftoandrogenreceptors;thiscausesittointeractwiththepartsofthecellinvolvedinthemakingofproteins.Itmaycauseanincreaseinthesynthesisofsomeproteinsoradecreaseinthesynthesisofothers.Theseproteinsh***eavarietyofeffects,includingblockingthegrowthofsometypesofbreastcancercells,stimulatingcellsthatcausemalesexualcharacteristics,andstimulatingtheproductionofredbloodcells.Sincetheeffectsofcastrationinpremenopausalwomenarefarsuperiortothoseofandrogenictherapy,themalehormonesh***ebeenemployedprimarilyforwomenofpostmenopausalage.Halotestinisusedonlyoccasionallybecauseotherhormonaltherapymedicinessuchas***andthearomataseinhibitorsaregenerallymoreeffective.Breastcancerisamalignancy(abnormalcells)arisinginthemammaryglands.Itaffectsbothmenandwomen,althoughitisfarmorecommoninwomen.Eachyear,over230,000womenintheU.S.arediagnosedwithbreastcancer,andabout40,000womendiefromthediseaseeveryyear.Malebreastcanceraccountsforabout1%ofallbreastcancers.Androgenichormonesh***ebeeneffectivelyemployedinthetherapyofadvancedbreastcancer.Objectiveimprovementoccursinapproximately25percentofpatientswithosseousmetastases,withalowerrateofresp***einpatientswithsoft-tissuelesi***.Applicati***:Fluoxymesteroneisaman-madeformof***,anaturallyoccurringsexhormonethatisproducedinaman'stesticles.***allamountsof***arealsoproducedinawoman'sovariesandadrenalsystem.Fluoxymesteroneisusedinmenandboystotreatconditi***causedbyalackofthishormone,suchasdelayedpubertyorotherhormonalimbalances.Fluoxymesteroneisalsousedinwomentotreatbreastcancerthathasspreadtootherpartsofthebody.Fluoxymesteronetreatsonlythesymptomsofmetastaticbreastcancerbutdoesnottreatthecanceritself.Fluoxymesteronemaybetakenwithorwithoutfood.Ifstomachupsetoccurs,takewithfoodtoreducestomachirritation.Ifyoumissadoseoffluoxymesterone,takeitassoonaspossible.Ifitisalmosttimeforyournextdose,skipthemisseddoseandgobacktoyourregulardosingschedule.Donottake2dosesatsageisbasedonyourmedicalcondition,***bloodlevels,andresp***etotreatmentCOA:TESTITEMSSPECIFICATIONRESULTSDescriptionWhiteorAlmostWhiteCrystallinePowderWhitePowderIdentificationA.B.PositiveAssay97.0~102.0%98.60%SpecificRotation+104¡ã~+112¡ã+107.8¡ãLossOnDrying1.0%max0.36%ChromatographicPuritysingleimpurity:1.0%max<1.0%totalimpurities:2.0%max<2.0%OrganicVolatileImpuritiesmeetstherequirement.ConformsResidualSolventsmeetstherequirement.ConformsConclusionThespecificationconformwithUSP30standard)